Dominic ffytcheThe work has been carried out by Andrew Astle, a PhD college student at the University. ‘The results up to now show a drastic improvement on patching, and disprove the long-held belief that adults can’t be treated for this type of condition,’ Andrew said. ‘However, the study isn’t total and we’re still searching for subjects to be a part of the tests.’ Work set to start out in spring 2009 at the University will build on Andrew’s results, examining amblyopia in kids and examining the structural and useful organisation of the visual cortex. This EU-wide study provides been funded by a European Consortium FP7 grant to the tune of 2.6m Euro. Professor Paul McGraw and Dr Ben Webb in the Visible Neuroscience Group will look at the effects and treatment of amblyopia in children.Announced today that the firms possess signed a definitive agreement under which Bristol-Myers Squibb will acquire all the issued and outstanding capital stock of Cardioxyl, a private biotechnology company centered on the discovery and advancement of novel therapeutic brokers for the treatment of cardiovascular disease. The transaction includes upfront and near-term milestone payments as high as $300 million and potential additional consideration as high as $1.775 billion upon the achievement of certain development, regulatory and product sales milestones. The deal, which is likely to be dilutive to 2015 GAAP EPS by around $0.12, with reduced dilution to non-GAAP EPS in both 2015 and 2016, has been accepted simply by the boards of directors of both ongoing companies.